美国伯明翰髋关节表面置换植入物的五至十年结果:单中心经验
该单中心研究纳入314例患者(360髋)接受伯明翰髋关节表面置换(BHR),93%的存活患者髋关节随访至少5年。全因翻修Kaplan-Meier生存率5年为97.2%、10年为93.8%;符合现行BHR入选标准者无菌性翻修生存率5年99.5%、10年98.2%。配对队列分析显示BHR术后UCLA评分高于全髋关节置换,高活动患者中BHR术后UCLA评分下降更小且维持高活动可能性更大。
要点
- BHR全因翻修生存率5年97.2%(95%CI 94.7%-98.5%),10年93.8%(95%CI 88.8%-96.7%)。
- 符合现行入选标准者无菌性翻修生存率5年99.5%(95%CI 96.6%-99.9%),10年98.2%(95%CI 94.4%-99.4%)。
- 配对分析中BHR术后UCLA评分高于全髋关节置换(8.0±2.0 vs 7.6±1.8,p=0.040),高活动患者维持高活动比例61% vs 20%(p<0.001)。
核心结论
- BHR在选定患者中5至10年显示出优异的生存率和临床结果。
- 与全髋关节置换相比,BHR可能为高活动患者提供术后活动方面具有临床重要性的优势以及维持高活动的更大可能性。
- 需要继续随访以验证BHR的长期结果。
研究设计与样本
- 单中心研究,314例患者(360髋)接受BHR表面置换关节成形术并同意参与研究。
- 在存活患者的350髋中,93%(324髋)至少随访5年,收集患者报告结果、并发症和翻修数据。
- 采用配对队列分析比较BHR与全髋关节置换的临床结果,配对因素为术前UCLA评分、诊断、年龄、性别和体重指数。
主要发现
- 改良Harris髋关节评分(mHHS)和加州大学洛杉矶分校(UCLA)评分术后显著改善,分别达到89.9和8.0(p<0.001)。
- 全因翻修Kaplan-Meier生存率5年为97.2%(95%CI 94.7%-98.5%),10年为93.8%(95%CI 88.8%-96.7%)。
- 符合现行BHR入选标准(男性<60岁、骨关节炎诊断、解剖适合股骨头组件≥48 mm)者无菌性翻修生存率5年为99.5%(95%CI 96.6%-99.9%),10年为98.2%(95%CI 94.4%-99.4%)。
- 14例患者(占所有髋的4.3%)需要翻修。
- 配对队列分析中BHR术后UCLA评分显著高于全髋关节置换(平均8.0±2.0 vs 7.6±1.8,p=0.040);术前高活动(UCLA评分9-10)的配对患者中,BHR术后UCLA评分中位下降更小(0.0 vs 1.0,p<0.001),根据最小临床重要差异(MCID,0.92)具有临床重要性;BHR维持高活动的可能性更大(61% vs 20%,p<0.001)。
关键数值与推荐
- 当前BHR入选标准:男性<60岁、骨关节炎诊断、解剖适合股骨头组件≥48 mm。
- 全因翻修生存率5年97.2%(95%CI 94.7%-98.5%),10年93.8%(95%CI 88.8%-96.7%)。
- 符合入选标准者无菌性翻修生存率5年99.5%(95%CI 96.6%-99.9%),10年98.2%(95%CI 94.4%-99.4%)。
- 配对分析中BHR与全髋关节置换术后UCLA评分平均8.0±2.0 vs 7.6±1.8(p=0.040)。
- 高活动患者中BHR与全髋关节置换术后UCLA评分中位下降0.0 vs 1.0(p<0.001),维持高活动比例61% vs 20%(p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要继续随访以验证BHR的长期结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: International surgeon series and registry data have demonstrated positive outcomes and long-term survival of the Birmingham Hip Resurfacing (BHR) implant. We report the 5 to 10-year results from a single center in the U.S. METHODS: Three hundred and fourteen patients (360 hips) underwent surface replacement arthroplasty with use of the BHR implant and consented to study participation. Patient-reported outcomes and complication and revision data were collected at a minimum of 5 years of follow-up for 93% (324 of 350) of the hips in surviving patients. A matched-cohort analysis was used to compare clinical outcomes between use of the BHR and total hip arthroplasty. RESULTS: Mean modified Harris hip score (mHHS) and University of California, Los Angeles (UCLA) scores significantly improved postoperatively, to 89.9 and 8.0, respectively (p < 0.001). The Kaplan-Meier estimated rate of survival for all-cause revision was 97.2% (95% confidence interval [CI], 94.7% to 98.5%) and 93.8% (95% CI, 88.8% to 96.7%) at 5 and 10 years, respectively. In a subgroup analysis of patients fitting our current BHR inclusion criteria (males <60 years of age with a diagnosis of osteoarthritis and anatomy conducive to a femoral head component of ≥48 mm), survival free of aseptic revision was 99.5% (95% CI, 96.6% to 99.9%) at 5 years and 98.2% (95% CI, 94.4% to 99.4%) at 10 years. Fourteen patients (4.3% of all hips) required revision. Postoperative UCLA scores were significantly greater for BHR compared with total hip arthroplasty (mean score of 8.0 ± 2.0 versus 7.6 ± 1.8; p = 0.040) in a matched-cohort analysis, with patients matched according to preoperative UCLA score, diagnosis, age, sex, and body mass index. Among matched patients who were highly active preoperatively (UCLA score of 9 to 10), BHR provided a smaller median decrease in the postoperative UCLA score (0.0 versus 1.0; p < 0.001), which was clinically important according to the minimal clinically important difference (MCID, 0.92). Furthermore, BHR provided a greater likelihood of remaining highly active compared with total hip arthroplasty (61% compared with 20%; p < 0.001). CONCLUSIONS: BHR demonstrated excellent survivorship and clinical outcomes at 5 to 10 years in selected patients. As compared with total hip arthroplasty, the use of the BHR may provide highly active patients with clinically important advantages in postoperative activity as well as a greater likelihood of remaining highly active. Continued follow-up is necessary to validate long-term BHR outcomes. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
引用
- Ford MC, Hellman MD, Kazarian GS, et al. Five to Ten-Year Results of the Birmingham Hip Resurfacing Implant in the U.S.: A Single Institution's Experience. J Bone Joint Surg Am. 2018. PMID: 30399083. doi:10.2106/JBJS.17.01525
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。